SYN-004 is under clinical development by Synermore Biologics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SYN-004’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SYN-004 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SYN-004 overview

SYN-004 is under development for the treatment of solid tumors including head and neck cancer squamous cell carcinoma, metastatic colorectal cancer and non-small cell lung cancer. The drug candidate is administered through intravenous route. The drug candidate is a recombinant chimeric monoclonal antibody which acts by targeting epidermal growth factor receptor (EGFR).

Synermore Biologics overview

Synermore Biologics (Synermore) is a biotechnology company that researches and develops biosimilar monoclonal antibodies. It develops its products in the therapeutic areas of oncology, immune disorders and infectious diseases. Its pipeline products include SYN004, SYN008, SYN125, SYN050, SYN060, SYN112, SYN109 and others. Synermore has developed technologies and platforms necessary for the development and production of therapeutic monoclonal antibodies including preparation and screening of hybridomas, antibody engineering and humanization, cell line construction and screening, CHO cell based culture platforms for high-density antibody expression, fermentation and purification, advanced analytical technologies for antibody characterization, and antibody drug formulation. The company also operates though its office located in Suzhou, China. Synermore is headquartered in Taipei City, Taiwan.

Quick View SYN-004 LOA Data

Report Segments
  • Innovator
Drug Name
  • SYN-004
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.